Bank of America Merrill Lynch is out with its report today on Regeneron Pharmaceuticals REGN, maintaining Buy.
In a note to clients, Bank of America Merrill Lynch writes, "We rate REGN shares Buy, owing to a rich and undervalued pipeline of biologic therapies. Our DCF-derived PO of $65 is based on risk-adjusted revenue projections of the key pipeline products (VEGF Trap-Eye, rilonacept, aflibercept, antibody program). Current valuation leaves upside potential
for positive results from upcoming clinical trial data and potential milestone payments from development partners."
Bank of America Merrill Lynch maintains a $65 PO on REGN.
Shares of REGN closed Thursday at $55.77, down 1.74% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsBank of America Merrill LynchBiotechnologyHealth CareRegeneron Pharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in